Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) EBITDA (2022 - 2025)

Atara Biotherapeutics (ATRA) has disclosed EBITDA for 4 consecutive years, with -$4.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 80.34% year-over-year to -$4.3 million, compared with a TTM value of $23.4 million through Sep 2025, up 117.64%, and an annual FY2024 reading of -$85.2 million, up 68.94% over the prior year.
  • EBITDA was -$4.3 million for Q3 2025 at Atara Biotherapeutics, down from $2.4 million in the prior quarter.
  • Across five years, EBITDA topped out at $38.0 million in Q1 2025 and bottomed at -$89.6 million in Q1 2022.
  • Average EBITDA over 4 years is -$36.9 million, with a median of -$31.6 million recorded in 2024.
  • The sharpest move saw EBITDA plummeted 499.12% in 2023, then surged 220.25% in 2025.
  • Year by year, EBITDA stood at -$73.7 million in 2022, then rose by 18.45% to -$60.1 million in 2023, then soared by 78.85% to -$12.7 million in 2024, then surged by 66.15% to -$4.3 million in 2025.
  • Business Quant data shows EBITDA for ATRA at -$4.3 million in Q3 2025, $2.4 million in Q2 2025, and $38.0 million in Q1 2025.